Slate Medicines raised a $130 million Series A round to advance a migraine and headache drug it in-licensed from DartsBio (Guangdong) Pharmaceuticals, the company said Tuesday.
Why it matters: Slate's drug candidate is targeting a pathway drugmakers are racing to validate.
